Press release
Malignant Mesothelioma Clinical Pipeline | 20+ Companies, Including Epizyme, Ys Therapeutics, and Polaris Pharmaceuticals, Driving Treatment Innovations
Malignant Mesothelioma Clinical Pipeline
DelveInsight's 'Malignant Mesothelioma Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Malignant Mesothelioma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Malignant Mesothelioma pipeline domain.
For emerging Malignant Mesothelioma drugs, the Malignant Mesothelioma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Malignant Mesothelioma Pipeline Report
• DelveInsight's Malignant Mesothelioma Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline drugs for Malignant Mesothelioma treatment.
• The leading Malignant Mesothelioma companies include Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, Polaris Pharmaceuticals, Merck, Vivace Therapeutics, Shionogi, Mirati Therapeutics, Incyte Corporation, TCR2 Therapeutics, SOTIO Biotech, Pfizer, Ascentage Pharma, Fida Farmaceutici, and others are evaluating their lead assets to improve the Malignant Mesothelioma treatment landscape.
• Key Malignant Mesothelioma pipeline therapies in various stages of development include INCB001158, RSO-021, Pegargiminase, PrE0505/ PrE0506, Volrustomig, and others.
• In September 2024, the FDA approved pembrolizumab (KEYTRUDA) in combination with pemetrexed and platinum chemotherapy as a first-line treatment for unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Request a sample and discover the recent breakthroughs happening in the Malignant Mesothelioma pipeline landscape @ https://www.delveinsight.com/report-store/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Malignant Mesothelioma Overview
Malignant mesothelioma is a rare cancer arising from mesothelial cells, primarily linked to asbestos exposure. These cells form the protective lining around various organs, with the pleura being the most commonly affected site, leading to malignant pleural mesothelioma. While mesothelioma can also develop in the peritoneum or pericardium, the lifetime risk for asbestos workers is estimated at 10%, with documented exposure present in up to 70% of cases.
The symptoms of mesothelioma are often nonspecific and can resemble other intrathoracic conditions, both benign and malignant. Common signs include a persistent, typically nonproductive cough, dyspnea, and chest wall pain, often described as a localized ache. Patients may also present with palpable soft tissue masses, reduced breath sounds, and dullness to percussion due to pleural effusion. In some cases, mesothelioma can cause splinting or even scoliosis toward the affected side.
Find out more about Malignant Mesothelioma medication @ https://www.delveinsight.com/report-store/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Malignant Mesothelioma Treatment Analysis: Drug Profile
INCB001158: Incyte Corporation
INCB001158 (CB-1158) is an investigational first-in-class small-molecule arginase inhibitor. Arginase, an enzyme secreted by various tumor-associated cells such as myeloid-derived suppressor cells, macrophages, and neutrophils, depletes L-arginine from the tumor microenvironment, suppressing immune responses. By inhibiting arginase, INCB001158 aims to restore L-arginine levels, enhance T-cell function, and promote anti-tumor immune activity by improving proliferation, cytokine production, and CD3ζ expression.
RSO-021: RS Oncology
RSO-021 is a novel irreversible inhibitor targeting PRX3, a mitochondrial enzyme upregulated in cancer cells that regulates oxidative stress pathways. It is designed to be administered weekly via an intrapleural catheter following routine pleural effusion drainage, offering a potential therapeutic approach for cancer treatment.
Key Malignant Mesothelioma Therapies and Companies
• INCB001158: Incyte Corporation
• RSO-021: RS Oncology
• Pegargiminase: Polaris Pharmaceuticals
• PrE0505/ PrE0506: PrECOG
• Volrustomig: Astrazeneca
Learn more about the novel and emerging Malignant Mesothelioma pipeline therapies @ https://www.delveinsight.com/report-store/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Malignant Mesothelioma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intravenous
• Intramuscular
• Oral
• Subcutaneous
By Molecule Type
• Small Molecule
• Gene Therapy
• Stem Cell Therapy
• Antidepressants
Scope of the Malignant Mesothelioma Pipeline Report
• Coverage: Global
• Key Malignant Mesothelioma Companies: Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, Polaris Pharmaceuticals, Merck, Vivace Therapeutics, Shionogi, Mirati Therapeutics, Incyte Corporation, TCR2 Therapeutics, SOTIO Biotech, Pfizer, Ascentage Pharma, Fida Farmaceutici, and others.
• Key Malignant Mesothelioma Pipeline Therapies: INCB001158, RSO-021, Pegargiminase, PrE0505/ PrE0506, Volrustomig, and others.
Dive deep into rich insights for drugs used for Malignant Mesothelioma treatment; visit @ https://www.delveinsight.com/report-store/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Malignant Mesothelioma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Malignant Mesothelioma Pipeline Therapeutics
6. Malignant Mesothelioma Pipeline: Late-Stage Products (Phase III)
7. Malignant Mesothelioma Pipeline: Late-Stage Products (Phase III)
8. Malignant Mesothelioma Pipeline: Mid-Stage Products (Phase II)
9. Malignant Mesothelioma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Malignant Mesothelioma Clinical Pipeline | 20+ Companies, Including Epizyme, Ys Therapeutics, and Polaris Pharmaceuticals, Driving Treatment Innovations here
News-ID: 3933684 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Malignant
Malignant Mesothelioma Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Malignant Mesothelioma Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections-Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.
Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.
Report Highlights
Publisher's Pharmaceutical…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result,…
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. Global Malignant Melanoma Drug Market Future Prospects
6. Global Malignant Melanoma Clinical Pipeline By…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
